Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirolimus-generated donor Th2 cells
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Sirolimus-generated donor Th2 cells are an investigational adoptive cellular immunotherapy consisting of allogeneic donor T cells that have been cultured *ex vivo* in the presence of interleukin-4 (IL-4) and sirolimus (rapamycin). Sirolimus, a potent inhibitor of the mechanistic target of rapamycin (mTOR), is used during the manufacturing process to selectively inhibit the differentiation of proinflammatory Type 1 (Th1) and Type 1 cytotoxic (Tc1) T cells. This process biases the T-cell population toward a Type 2 (Th2) helper phenotype, which is associated with the production of anti-inflammatory cytokines. When infused into patients following allogeneic hematopoietic stem cell transplantation (HSCT), these cells are intended to modulate the recipient's immune system, reducing the incidence and severity of graft-versus-host disease (GVHD) by shifting the immune environment from a Th1/Tc1-mediated inflammatory state to a Th2-mediated regulatory state. Importantly, this approach seeks to preserve the graft-versus-tumor (GVT) effect, as the GVT response can be mediated by non-mTOR dependent pathways or specific Th2 subsets.
- Other names
- sirolimus-conditioned donor Th2 cellsrapamycin-generated donor Th2 cellsrapamycin-treated donor Th2 cellsdonor Th2 cells
Beyond the preview
Go deeper on sirolimus-generated donor Th2 cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirolimus-generated donor Th2 cells.